COCP - Cocrystal Pharma Inc. (COCP) - Promising Preclinical Data from Coronavirus Program

Coronavirus program preclinical study results are published. Cocrystal announced that animal study results of coronavirus antiviral compounds are published in Science Translational Medicine, one of the most prestigious medical journals. The publication highlights the mechanism action of the anti-viral compounds and the survival results of mice treated with these compounds. Cocrystal and Kansas State University Research Foundation (KSURF) have a license agreement. The publication highlights preclinical data of KSURF inhibitors.Anti-viral compounds reduced lung infection and increased survival in mice. The preclinical data suggest anti-viral compounds are protease inhibitors (3CLpro inhibitors) that are essential for viral replication. The lead compound reduces lung viral load and lung pathology and also prolongs the survival of infected mice. The data also emphasizes the importance of early therapeutic intervention in attaining a positive clinical outcome. The earlier initiation of treatment results in significant improvement in the survival rate of mice.Reiterating Outperform rating. In our opinion, the preclinical results are promising. The company will select the lead compound in Q4 2020 after preclinical studies of inhibitors received from KSURF and additional inhibitors identified using its proprietary platform technology. We foresee value expansion upon meaningful preclinical data and advancement of coronavirus program into the clinic. We are reiterating our Outperform rating and $5 price target.Read More >>